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We thank the reviewer for his/her careful and valuable work. We believe that, by responding to his/her 
points, the study processes have been better detailed. This was possible as we moved the Methods, the 
Acknowledgements, Funding, and Conflict of interest to the Supplementary Appendix. For point 7, we did 
our best to match information provision and the available space. 
 
1. The authors state in their revised methods that they used a deductive qualitative approach, which is a 
very helpful clarification. If this is the case, though, then there should be a statement in the methods of 
[1a] a theory/hypothesis that they were testing, a testable proposition, or a model that they were 
seeking to support. [1b] Was there a specific type of deductive qualitative approach used, such as 
pattern matching? [1c] Also, if the point of the analysis was simply to identify important outcomes from 
the discussion and all other comments/topics raised by participants were ignored, this should be 
explicitly stated.   
[1a] We now specify in the Methods (Appendix): ‘As we were particularly interested in understanding 
patient values we thought that MS patients and their caregivers would have been more prone to 
discuss in a dedicated setting the guideline questions. In doing so we expected to find across the data 
themes mainly related to the clinical questions.’
[1b] We did not use any specific type of deductive qualitative approach.  
[1c] We believe that the focus of the FGMs (i.e. of the qualitative analysis) is detailed in Table 5 (aims): 
‘Explain/discuss the process of guideline production; Identify outcomes important to patient and 
caregivers; Explore ‘difficult’ topics and taxing issues.’ Note that it is further mentioned in the 
Discussion: ‘The FGMs allowed the explanation of the process of guideline production, the 
identification of patient-important outcomes, and deliberation about taxing issues (Table 5)’. 
 
2. Edited to add – this is mentioned briefly in the discussion with the sentence, “The deductive analysis 
was linked to the preformed questions and themes derived from the literature and consensus, and was 
not aimed to produce an interpretative model” but this needs to be described in the methods. I don’t 
feel strongly about this being mentioned as a limitation as long as the methods are clear about the 
intent and process of the qualitative analysis.  
We have changed the manuscript following the reviewer’s advice - Methods: ‘The deductive qualitative 
analysis was linked to the pre-formed questions and themes derived from the literature and consensus, 
and was not aimed to produce an interpretative model.’  
 
3. The COREQ checklist mentions that in the Milan focus group, a research assistant was needed to help 
the disabled patients (eg in drinking, changing position). This kind of detail is important for guideline 
developers hoping to replicate the work that current authors have done. This “practical support” is a 
theme previously reported as important to patient engagement in guideline panels (Armstrong et al. 
Recommendations for patient engagement in guideline development panels: A qualitative focus group 
study of guideline-naïve patients. PLOS One 12(3):e0174329). It would be useful to add this information 
to the main manuscript as an example of both the resource-intensive nature of patient engagement but 
also how to make sure it is done well.  
We have changed the manuscript following the reviewer’s advice -  Methods: ‘In the Milan FGM of 
patients a research assistant also attended, to help participants (e.g. in drinking, changing position).’  
 































































4. It is not clear why the UK results were excluded from the analysis (as per Table 2, text) simply because 
the desired number of participants was not reached. While the low response rate is unfortunate, 
excluding completed surveys brings in more bias than including them. Additionally, there are ethical 
concerns with excluding data of consented participants. Such concerns are obviously greater when 
patients have endured more risk for a study than a survey, but some of the ethical principles are the 
same. If there is a methodologic reason for excluding them, this should be stated. It makes sense that 
there weren’t sufficient numbers to inform a by-country analysis (UK responses versus responses from 
other countries) but in an analysis whose primary outcome is to identify outcomes important to 
patients, it is not clear why patient voices were excluded?  
As from the Methods, the guideline task force set a priori the minimum number of participants 
required to deem that a given country contributed to the study findings. This decision was taken 
besides any cross-country comparison purpose, to substantiate the countries characterized in the 
survey. In the UK (the second country  in terms of inhabitants and number of MS patients, see Table 1) 
participants were 17, a value well below the threshold of 50. There is no need for a sensitive analysis to 
prove that inclusion of these data would not have changed the overall study findings. We do not see 
any ethical concern in this, and we did not want to exclude patient voices. Rather, these findings 
indicate that online surveys are increasingly performed by patient organizations, and careful planning is 
needed. The online survey was unsuccessful in the UK. Nevertheless, the results of the study will be 
made available to the scientific community and (via the International MS Federation and the NMSSs) to 
the patients.            
 
5. Is there a reason that partial surveys were not used for the questions for which there were responses? 
The reason for excluding partial surveys is not provided.  
As reported in the Methods, the demographic section had ‘a common set of multiple choice items on 
participant age, sex, education, status (patient or caregiver), and specific multiple choice questions for 
patients (time from MS diagnosis, disability level, employment status) and caregivers (relation with the 
MS sufferer, time from MS diagnosis, disability level, employment status of the MS sufferer)’. As we 
aimed to characterize participants, and to compare the findings of the patients and caregivers, we 
excluded from the analysis those participants who abandoned the survey without providing the key 
information regarding their status (and the status-specific questions). We have now specified this in the 
Results: ‘The analysis was performed on 934 participants from seven countries who provided 
information on their status (MS patient or caregiver) (Table 2).’ We have reported in the Table below 
for the reviewer the pattern of the responses of these participants. In the manuscript this finding is 
summarized in the Results as follows: ‘High rates of agreement were obtained also from participants 
excluded from the analysis as they did not provide information on their status (data not shown).’    
   
 Strongly 
agree 






Topic N (%) 
1. Symptomatic treatments  68 (43) 76 (48) 3 (  2) 1 (1) 10 (  6) 158 
2. Multidisciplinary rehabilitation  56 (51) 51 (47) 1 (  1) 0   1 (  1) 109 
3. Timely engagement in advance care planning  35 (44) 40 (51) 1 (  1) 0   3 (  4)   79 






























































4. General palliative care  28 (45) 29 (46) 5 (  8) 0   1 (  1)   63 
5. Specialist palliative care  21 (50) 19 (46) 1 (  2) 1 (2)   0   42 
6. Education/training programs for caregivers  14 (36) 17 (44) 4 (10) 0   4 (10)   39 
7. Practical/emotional support to caregivers  16 (45) 13 (37) 3 (  9) 0   3 (  9)   35 
8: Education/training in palliative care for MS HPs 14 (44) 17 (53) 0 0   1 (  3)   32 
9. Education/training in MS for palliative care HPs 11 (40) 15 (56) 0 0   1 (  4)   27 
 
 
6. There is no information in the methods about how themes were determined for the write-in 
answers/comments on the survey. (This is essentially a qualitative-type analysis of write-in responses 
and the approach to categorizing the comments can easily be added to the methods for clarity.)  
We have now detailed this in the Methods: ‘Two researchers (AG, AF) coded the open section on 
additional topics independently and jointly as follows: they devised two lists of response categories, 
one for the interventions and one for the outcomes; additional categories identified during the coding 
process were included to the pertinent list; if a comment included multiple topics, it was coded it into 
multiple categories.  A third researcher (AS) was involved in case of difficult attribution.’   
 
7. While the results of patient engagement are now stated more explicitly in the text and Table 5 and this 
is very helpful, the discussion still has no framing of the study results in the context of the broader 
literature. Authors identified that engaging patients impacted the questions asked for the guideline. Is 
this consistent with what is reported in the literature? How do these findings relate to the broader work 
in this field? Are results consistent with prior findings or new? The answer is that these findings are 
consistent with what is described previously and this should be discussed. Such a discussion will 
strengthen the impact of this study, as it will demonstrate that this work adds to the growing body of 
literature showing that engaging patients in guideline development impacts guideline development 
(here, specifically relating to selection of topics/questions). Setting patient-centered scope is one 
identified result of patient engagement in guidelines (Tong 2011 [Tong, A., et al., Consumer 
involvement in topic and outcome selection in the development of clinical practice guidelines. Health 
Expectations, 2011. 15: p. 410-423.], Diaz del Campo 2011 [Diaz Del Campo, P., et al., A strategy for 
patient involvement in clinical practice guidelines: methodological approaches. BMJ Qual Saf, 2011. 
20(9): p. 779-84.], Brouwers 2017 [Brouwers, M.C., et al., Understanding optimal approaches to patient 
and caregiver engagement in the development of cancer practice guidelines: a mixed methods study. 
BMC Health Serv Res, 2017. 17(1): p. 186.]), as are identifying issues that may be overlooked by medical 
professionals (Jarrett 2004 [Jarrett, L. and P.I. Unit, A report on a study to evaluate patient/carer 
membership of the first NICE Guideline Development Groups. 2004], Cowl 2015 [Cowl, J., et al., Chapter 
1: How to conduct public and targeted consultation, in G-I-N Public Toolkit: Patient and Public 
Involvement in Guidelines (2015 ed). 2012, Guidelines International Network: Pitlochry, Scotland.], van 
der Ham 2016 [van der Ham, A.J., N. van Erp, and J.E. Broerse, Monitoring and evaluation of patient 
involvement in clinical practice guideline development: lessons from the Multidisciplinary Guideline for 
Employment and Severe Mental Illness, the Netherlands. Health Expect, 2016. 19(2): p. 471-82.], Den 
Breejen 2016 [den Breejen, E.M., et al., Added value of involving patients in the first step of 
multidisciplinary guideline development: a qualitative interview study among infertile patients. Int J 
Qual Health Care, 2016. 28(3): p. 299-305.]) and selecting patient-relevant topics and outcomes (Jarrett 
2004, Tong 2011, Graham 2006 [Graham, K. Patient/carer involvement in clinical guidelines: the SIGN 






























































experience, Scottish Intercollegiate Guidelines Network. in Presented at the conference of the Spanish 
HTA group. 2006. Seville, Spain.], Légaré 2011, Diaz del Campo 2011, Guyatt 2011 [Guyatt, G.H., et al., 
GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol, 2011. 
64: p. 395-400.], Coon 2016 [Coon, J.T., et al., End-user involvement in a systematic review of 
quantitative and qualitative research of non-pharmacological interventions for attention deficit 
hyperactivity disorder delivered in school settings: reflections on the impacts and challenges. Health 
Expect, 2016. 19(5): p. 1084-97.]). Useful reviews that could be cited include Légaré 2011 (Légaré, F., et 
al., Patient and public involvement in clinical practice guidelines: A knowledge synthesis of existing 
programs. Med Decis Making, 2011. 31: p. E45-E74) and/or Armstrong 2018 (Armstrong, M.J., et al., 
Impact of patient involvement on clinical practice guideline development: a parallel group study. 
Implement Sci, 2018. 13:55). Regardless of the specific references chosen, there needs to be some 
discussion of the current work in the context of similar research to identify the contribution that this 
work makes to an expanding field. Such a discussion will make the current work more impactful 
because it will frame these results in the context of an important and expanding body of work 
demonstrating the value of patient engagement at the step of guideline question development. The 
answer is that these findings are consistent with what is described previously and this should be 
discussed. Such a discussion will strengthen the impact of this study, as it will demonstrate that this 
work adds to the growing body of literature showing that engaging patients in guideline development 
impacts guideline development (here, specifically relating to selection of topics/questions).  
We have widened the Discussion on this regard, by adding a sentence and two references (to comply 
with the manuscript length limits): ‘Our findings add to the growing body of literature showing that 
engaging patients in guideline development is feasible, and impacts the process (here, the selection 
and formulation of the guideline questions) [14, 15, 17, 18].’ The references added are Légaré F et al. 
2011; Armstrong MJ, et al. 2018. 
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Background: Patient and public involvement in clinical practice guideline development is 
recommended to increase guideline trustworthiness and relevance.  
Objective: To engage multiple sclerosis (MS) patients and caregivers in definition of the key questions 
to be answered in the EAN Guideline on Palliative Care of People with Severe MS. 
Methods: A mixed methods approach was used: International online survey launched by the national 
MS societies of eight countries, after pilot testing/debriefing on 20 MS patients and 18 caregivers; 
focus group meetings (FGMs) of Italian and German MS patients and caregivers.  
Results: Of 1199 participants, 951 (79%) completed the whole online survey, and 934 from seven 
countries were analyzed: 751 (80%) were MS patients (74% women, mean age 46.1) and 183 (20%) 
caregivers (36% spouses/partners, 72% women, mean age 47.4). Participants agreed/strongly agreed 
on inclusion of the nine pre-specified topics (from 89% for ‘advance care planning’ to 98% for 
‘multidisciplinary rehabilitation’), and <5% replied ‘I prefer not to answer’ to any topic. There were 
569 free comments: 182 (32%) on the pre-specified topics, 227 (40%) on additional topics (16 
guideline-pertinent), and 160 (28%) on outcomes. Five FGMs (three of MS patients, two of caregivers, 
overall 35 participants) corroborated the survey findings. In addition, they allowed the explanation of 
the guideline production process, the exploration of patient-important outcomes and of taxing issues. 
Conclusions: MS patient and caregiver involvement was resource and time intensive, but rewarding. 
It was key for the formulation of the 10 guideline questions, and for the identification of patient-
important outcomes.  
  































































The incorporation of patient values into individual clinical decisions, a fundamental of shared decision 
making, also applies to clinical practice guideline development [1]. The ultimate aim is to address the 
issues that are important to health consumers (patients, caregivers, and the public) and sensitive to 
their values and preferences. Consequently, professional societies and other guidelines producers 
have recognized the need to involve consumers in all the phases of guideline development [2]. An 
initial and fundamental guideline phase is the formulation of the clinical questions, specifying the 
population, intervention, comparator, and outcomes (PICO) [3]. For complex healthcare interventions, 
formulating PICO questions is more challenging than for questions of drug interventions, and no 
guidance currently exists [4,5]. The engagement of healthcare consumers is even more important to 
facilitate the operational definition of these questions.  
The European Academy of Neurology (EAN) has recently appointed a guideline production group 
(‘task force’ in the EAN guideline terminology) [6] to devise a clinical practice guideline on palliative 
care of people with severe multiple sclerosis (MS). The task force consists of health professionals from 
three disciplines (neurology, palliative care, and rehabilitation), methodologists, and patient 
advocates. Task force members are from nine European countries: Bulgaria, Germany, Denmark, 
Israel, Italy, the Netherlands, Serbia, Spain, and the UK.  
The guideline PICO questions were formulated obtaining information on patient values from literature 
search, from expert survey, and from the direct engagement of MS patients and caregivers using a 
mixed methods (quantitative and qualitative) approach. Here we describe the results of this process, 
and the main challenges encountered.  
 
 






























































MATERIALS AND METHODS  
The construction of the international online survey, its implementation, the focus group meetings 
(FGMs), the ethics statement, and analyses are reported in the Appendix. 
 
RESULTS 
Expert survey  
The expert survey took place in April 2017 (Figure): task force members invited health professionals to 
complete a questionnaire that contained an introduction, two open sections (on interventions and 
clinical outcome measures to be included in the guideline), and a section with respondent profession 
and expertise. Forty-seven health professionals from eight countries (Denmark, Germany, Italy, Israel, 
the Netherlands, Serbia, Spain, UK) participated. Most professionals (27) were physicians 
(neurologists, physiatrists, palliative care physicians), eight were nurses, six therapists 
(physiotherapists, psychologists, occupational therapists), three social workers, one research 
coordinator, one hospice coordinator, one chaplain.  
 
[Insert Figure about here] 
 
Based on review of the literature [7-11] and on expert survey findings, the task force agreed on a set 
of 14 items (‘questions’), which are reported in Table S3 (right column).  
 
Piloting of the international online survey  
The first version of the survey was discussed in dedicated meetings of the Danish MSS and the Israel 
MSS, and was piloted/debriefed on 20 MS patients and 18 caregivers from six European countries 






























































(Bulgaria, Germany, Italy, the Netherlands, Serbia, UK). In the Israel MSS meeting it was agreed that a 
survey on MS palliative care in Israel was too premature, as the discussion of palliative care, and 
death and dying was felt to be particularly difficult within the Israeli culture at this time. The 
interrogative item format (Table S3) and the section on outcomes related to each item (not shown) 
were found difficult to understand, and rate; the explanation paragraph of each item was considered 
complex; five of the 14 items were judged too taxing. As a result, the following changes were made to 
the first version: an affirmative item format was used; the list of outcomes attached to each question 
was removed; the explanation paragraph of each item was simplified; five items were removed (Table 
S3).  
 
Survey implementation, and findings  
Between July and December 2017, the online survey was carried out in all the task force countries, 
except Israel (see above). Participation was overall good, except for the UK (Table 1).  
 
[Insert Table 1 about here] 
 
The analysis was performed on 934 participants from seven countries who provided information on 
their status (MS patient or caregiver) (Table 2). MS patients (751, 80%) outnumbered caregivers (183, 
20%). Mean patient age was 46.1 years (range 19-82); 558 (74%) were women, and 428 (57%) had 
tertiary education (college or university degree). Notably, 49% of the patients were fully ambulatory, 
and 23% had been diagnosed within the last five years, with consistent figures across all the countries 
except the Netherlands where the MS patients were more disabled, indicating that MS patients were 
interested in the topic of palliative care regardless of their clinical status. Patient employment status 






























































varied, with highest unemployment in Spain and Bulgaria (14%), and lowest values in the Netherlands 
and Denmark (0-3%). Most of the caregivers were women (72%), their mean age was 47.4 years 
(range 18-77), and 64% had tertiary education. One third of the caregivers were the patient’s spouse 
or partner. The MS patients they cared for were of similar age (p=0.39) and disease duration (χ2 3.2; 
p=0.20) albeit more disabled (χ2 48.4; p<0.001) compared to the patients who completed the survey. 
The median (interquartile range) survey completion time was 8 (5-10) minutes in patients and 8 (6 - 
11) minutes in caregivers (p=0.07).  
 
[Insert Table 2 about here] 
 
Participants replying ‘I prefer not to answer’ were consistently few among MS patients and caregivers, 
highest values were found for ‘advance care planning’ (ACP: 4% of MS patients, and 5% of caregivers), 
and ‘specialist palliative care’(3% of MS patients, and 4% of caregivers). Participants agreed or 
strongly agreed on inclusion of the nine pre-specified topics, with the lowest value for ‘ACP’ (89% of 
both patients and caregivers) and the highest value for ‘multidisciplinary rehabilitation’ (99% of MS 
patients, 97% of caregivers). These figures were close to those of the 231 participants excluded from 
the analysis as they did not provide information on  their status (data not shown). 
 
There were 569 free comments, categorized into four domains: guideline pre-specified topics (182 
comments, 32%); additional topics, pertinent to the guideline (16 comments, 3%); additional topics, 
not pertinent to the guideline (211, 37%), and outcomes (160, 28%). Table 3 reports distribution of 
the comments across the four domains by country; details on domain contents are reported in the 
legend. 































































[Insert Table 3 about here] 
 
One-third of the comments on pre-specified guideline topics were on symptom management and 
rehabilitation - it was not possible from the comments to separate rehabilitation from 
multidisciplinary rehabilitation, thus topics 1 and 2 were merged, followed by palliative care and 
specialist palliative care (23%), and by emotional and practical support for caregivers (16%).  
The two guideline-pertinent additional topics were: ‘voluntary euthanasia’ (related to question 14; 
Table S3) proposed by 12 patients from Denmark, Germany, the Netherlands, and Italy, and three 
caregivers from Denmark and Germany; ‘sheltered housing/assisted living’, proposed by one German 
patient.  
Additional topics not pertinent to the guideline population, but to MS patients at large, regarded four 
main domains: ’welfare’ (104/211 comments, 49%), ‘empowerment’ (54 comments, 25%), ‘disease 
management’ (mainly related to the MS diagnosis; 31 comments, 15%), and ‘lifestyle’ (23 comments, 
11%).  
Fourteen overarching outcomes were mentioned, which included patient outcomes (from patient 
participation and quality of life, to quality of death and dying), caregiver outcomes, care-related 
outcomes, and costs (Table 3). 
Of 934 participants, 120 (13%) commented on the survey or on the guideline project. Of those, most 
participants (110, 92%) expressed appreciation of the initiative. Ten participants (8%) reported some 
criticisms: three patients considered the survey as not exhaustive, useless, or futile; one patient 
commented that topics 8 and 9 were the same; six participants criticized the patient general section 
of the survey. 































































FGM findings  
Patient FGMs lasted 96, 105, and 110 minutes, two had seven participants, and one 11 participants 
(total n=25). The median age of the patients was 54 years (range 53–75), 19 (76%) were women, and 
the median EDSS was 8.0 (range 6.0–9.5). Caregiver FGMs lasted 120 and 79 minutes, both with five 
participants (total n=10); their median age was 56 years (range 44–86), six (60%) were women; they 
were the spouse (n=5), widow (n=2) or widower (n=1) of MS patients who died in the previous year, 
mother (n=1), and daughter (n=1). After a short introduction and ice-breaking, 30-40 minutes were 
dedicated to the description of the guideline, the main phases of its production, and the reasons for 
involving patients and caregivers from the formulation of the clinical questions. All participants 
considered the guideline a valuable and necessary instrument for all professionals caring for people 
with severe MS: physicians (included family and emergency care physicians), therapists, nurses, social 
workers, and formal and informal caregivers.  
The FGM themes, components, and illustrative citations are reported in Table 4. Participants who had 
not been in touch with palliative care benefited from the explanation and discussion, as most of them 
thought the discipline pertained exclusively to end-of-life care and cancer (citations 1-3). This was 
different for participants who had experienced palliative care (citations 4,5). End-of-life issues did 
crop up as a key guideline topic (citations 6-10). Another theme was that of requirements for severely 
affected MS patients: peer socialization (citations 11, 12); and case management, expressed by both 
relatives and patients (citations 13, 14), who often felt overwhelmed and unsupported, for instance 
after discharge from hospital and rehabilitation. Outcomes encompassed symptom control (citations 
1, 3, 4), quality of life (citation 3), role preservation (of both patient and caregiver – citations 15,16), 
participation (citation 17), competency of professionals and caregivers (citations 18, 19), quality of 






























































care (citation 5), living will (citation 7), and caregiver burden (citation 10). In Germany patients’ 
emotional well-being and quality of life were considered the most important guideline outcomes, 
while unplanned hospitalizations and costs were seen as the least important. 
 
[Insert Table 4 about here] 
The main outcomes and challenges of the patient and caregiver consultation are summarized in Table 
5. Based on these findings, the task force formulated the guideline questions, and detailed each PICO 
component (Table S4). Four of the original questions (Table S3) were deemed of lesser importance, 
and subsidiary to specific guideline questions:  original question 6 ‘early palliative care’ to PICO 
question 4; original question 8 ‘goal setting’ to PICO questions 2, 4, 5;  original question 11 
‘anticipation of crises’ to PICO question 5; and original question 12 ‘best place of palliative care’ to 
PICO questions 4, 5.  




Offering the best care possible to the highest number of patients and reducing variations in service 
delivery are key issues for most healthcare systems, and the main reason for producing clinical 
practice guidelines [13]. Involvement of health service users in clinical guideline production has long 
been advocated, but insufficiently undertaken, and the best ways to engage users remain unclear [14-
16]. Here we report the experience of an international patient and caregiver involvement, which was 
time and resource intensive, and employed a mixed method. A crucial role in this process was played 
by the NMSSs of each participating country, and particularly by a task force member who is a MS 






























































patient and also a member of the MS International Federation, and of the Danish NMSS. She was key 
in bridging the issues of the MS patients to those of the health professionals and researchers. The 
online survey allowed participation of a geographically varied population, and by being anonymous 
facilitated openness and trustworthiness. However, it required proficiency with online technology, 
and the contents of the first survey were streamlined to improve clarity and acceptability. Findings 
indicated that the survey was well accepted (skipped topics were < 5%, negative comments were 
rare) and information-rich: MS patients and caregivers consistently agreed on the inclusion of the 
nine proposed topics, and provided additional proposals and comments (Table 5).  
The FGMs allowed the explanation of the process of guideline production, the identification of 
patient-important outcomes, and deliberation about taxing issues (Table 5).  The consultation process 
as a whole was time and resource intensive (figure). It was rewarding for the formulation of key 
questions that were substantiated by patients and caregivers, and also for the recognition of 
subsidiary topics within the guideline scope.        
Limitations. The online survey contents were not linguistically validated and participation differed 
markedly between countries. The FGMs could be organized only in two countries; not all the pre-
specified guideline topics could be discussed in the FGMs; the combination of previous and current 
caregivers in the same FGM was challenging (Table 5). The need for more time devoted to the task 




MS patients and caregivers validated the nine questions devised by our task force (with HP input), 
identified additional issues related to question 14 (voluntary euthanasia, assisted suicide), sheltered 






























































housing/assisted living, case management, and client-important overarching outcomes. This led to the 
formulation of 10 PICO questions for this guideline. Our pre-planned approach to engage patients and 
caregivers from the very beginning of guideline development is in line with current recommendations 
[3,16]. This was demanding but attainable, also at an international level.  Our findings add to the 
growing body of literature showing that engaging patients in guideline development is feasible, and 
impacts the process (here, the selection and formulation of the guideline questions) [14,15,17,18].  
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Additional Supporting Information may be found in the online version of this article:  
Supplementary Appendix. Materials and methods, acknowledgements, funding, and conflict of 
interest. 
Table S1. Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist. Items 30-32 were 
not completed as they do not imply the provision of information but a judgment on the analysis.  N.R. 
= not reported; N.A. = not applicable. 
Table S2. Focus group meeting guides. 
Table S3. The nine items (‘topics’) of the online survey (left column) are listed in the survey order. The 
14 items (‘questions’) of the first version are reported in the right column, for comparison. Items 10-
14 correspond to the removed items.  
Table S4. The 10 clinical questions formulated by the task force after completion of the consultation, 
each detailed in terms of population, intervention, comparator, outcomes, and setting. Outcomes 
reported in bold are those identified by patients and caregivers. 
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Figure legend. Flowchart and time points of the study. 
 






























































Full title: Patient and caregiver involvement in formulation of guideline questions: Findings from the 





, Andrea Giordano, MSc
2
, Simone Veronese, MD PhD
3





, Birgit Basedow-Rajwich, MD
5
, Arianna Fornari, MSc
2
, Mario Alberto Battaglia, MD 
PhD
6
, Jelena Drulovic, MD PhD
7
, Liesbeth Kooij, MSc
8
, Johan Koops, MD
8
, John Mens, MD
8
, Edwin 
Roger Meza Murillo, MD
9
, Ivan Milanov, MD PhD DSc
10
, Ron Milo, MD
11,12














, David J Oliver, MD FRCP
18




1. Institute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany 
2. Unit of Neuroepidemiology, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy 
3. FARO Charitable Foundation, Turin, Italy 
4. Institut für Neuroimmunologie und Multiple Sklerose (INIMS), Universitätsklinikum Hamburg-
Eppendorf, Hamburg, Germany 
5. Kempfenhausen Centre for Treatment of Multiple Sclerosis, Marianne-Strauß-Klinik, Berg, 
Germany 
6. Department of Life Sciences, University of Siena, Siena, Italy 
7. Clinic of Neurology, CSS, Faculty of Medicine, University Hospital of Belgrade, Belgrade, Serbia 
8. Nieuw Unicum, Zandvoort, Netherlands 
9. MS Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain 
10. Neurology Clinic, Medical University of Sofia, Sofia, Bulgaria 






























































11. Department of Neurology, Barzilai Medical Center, Ashkelon, Israel 
12. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel 
13. Neurology Clinic, Multiple Sclerosis Centre, University Hospital Policlinico Vittorio Emanuele, 
Catania, Italy 
14. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia 
15. Israel Multiple Sclerosis Society, Tel-Aviv, Israel 
16. Department of Palliative Medicine, University Hospital Cologne, Cologne, Germany 
17. Multiple Sclerosis International Federation, People with MS Advisory Committee, 
Copenhagen, Denmark 




Alessandra Solari, MD 
Unit of Neuroepidemiology  
Foundation IRCCS Neurological Institute C. Besta 
Via Celoria 11, 
20133 Milan, Italy 
E-mail: alessandra.solari@istituto-besta.it 
Tel. +390223944016; Fax +390223944056 
 
Total word count of the manuscript including title page, references, legends and structured 
abstract: 3472 






























































Running title: Patient and caregiver involvement in the formulation of guideline questions. 
Keywords: Multiple sclerosis; palliative care; best practice; clinical practice guideline; patient and 
public involvement; online survey; mixed methods. 
 































































Background: Patient and public involvement in clinical practice guideline development is 
recommended to increase guideline trustworthiness and relevance.  
Objective: To engage multiple sclerosis (MS) patients and caregivers in definition of the key questions 
to be answered in the EAN Guideline on Palliative Care of People with Severe MS. 
Methods: A mixed methods approach was used: International online survey launched by the national 
MS societies of eight countries, after pilot testing/debriefing on 20 MS patients and 18 caregivers; 
focus group meetings (FGMs) of Italian and German MS patients and caregivers.  
Results: Of 1199 participants, 951 (79%) completed the whole online survey, and 934 from seven 
countries were analyzed: 751 (80%) were MS patients (74% women, mean age 46.1) and 183 (20%) 
caregivers (36% spouses/partners, 72% women, mean age 47.4). Participants agreed/strongly agreed 
on inclusion of the nine pre-specified topics (from 89% for ‘advance care planning’ to 98% for 
‘multidisciplinary rehabilitation’), and <5% replied ‘I prefer not to answer’ to any topic. There were 
569 free comments: 182 (32%) on the pre-specified topics, 227 (40%) on additional topics (16 
guideline-pertinent), and 160 (28%) on outcomes. Five FGMs (three of MS patients, two of caregivers, 
overall 35 participants) corroborated the survey findings. In addition, they allowed the explanation of 
the guideline production process, the exploration of patient-important outcomes and of taxing issues. 
Conclusions: MS patient and caregiver involvement was resource and time intensive, but rewarding. 
It was key for the formulation of the 10 guideline questions, and for the identification of patient-
important outcomes.  
  































































The incorporation of patient values into individual clinical decisions, a fundamental of shared decision 
making, also applies to clinical practice guideline development [1]. The ultimate aim is to address the 
issues that are important to health consumers (patients, caregivers, and the public) and sensitive to 
their values and preferences. Consequently, professional societies and other guidelines producers 
have recognized the need to involve consumers in all the phases of guideline development [2]. An 
initial and fundamental guideline phase is the formulation of the clinical questions, specifying the 
population, intervention, comparator, and outcomes (PICO) [3]. For complex healthcare interventions, 
formulating PICO questions is more challenging than for questions of drug interventions, and no 
guidance currently exists [4,5]. The engagement of healthcare consumers is even more important to 
facilitate the operational definition of these questions.  
The European Academy of Neurology (EAN) has recently appointed a guideline production group 
(‘task force’ in the EAN guideline terminology) [6] to devise a clinical practice guideline on palliative 
care of people with severe multiple sclerosis (MS). The task force consists of health professionals from 
three disciplines (neurology, palliative care, and rehabilitation), methodologists, and patient 
advocates. Task force members are from nine European countries: Bulgaria, Germany, Denmark, 
Israel, Italy, the Netherlands, Serbia, Spain, and the UK.  
The guideline PICO questions were formulated obtaining information on patient values from literature 
search, from expert survey, and from the direct engagement of MS patients and caregivers using a 
mixed methods (quantitative and qualitative) approach. Here we describe the results of this process, 
and the main challenges encountered.  
 
 






























































MATERIALS AND METHODS  
The construction of the international online survey, its implementation, the focus group meetings 
(FGMs), the ethics statement, and analyses are reported in the Appendix. 
 
RESULTS 
Expert survey  
The expert survey took place in April 2017 (Figure): task force members invited health professionals to 
complete a questionnaire that contained an introduction, two open sections (on interventions and 
clinical outcome measures to be included in the guideline), and a section with respondent profession 
and expertise. Forty-seven health professionals from eight countries (Denmark, Germany, Italy, Israel, 
the Netherlands, Serbia, Spain, UK) participated. Most professionals (27) were physicians 
(neurologists, physiatrists, palliative care physicians), eight were nurses, six therapists 
(physiotherapists, psychologists, occupational therapists), three social workers, one research 
coordinator, one hospice coordinator, one chaplain.  
 
[Insert Figure about here] 
 
Based on review of the literature [7-11] and on expert survey findings, the task force agreed on a set 
of 14 items (‘questions’), which are reported in Table S3 (right column).  
 
Piloting of the international online survey  
The first version of the survey was discussed in dedicated meetings of the Danish MSS and the Israel 
MSS, and was piloted/debriefed on 20 MS patients and 18 caregivers from six European countries 






























































(Bulgaria, Germany, Italy, the Netherlands, Serbia, UK). In the Israel MSS meeting it was agreed that a 
survey on MS palliative care in Israel was too premature, as the discussion of palliative care, and 
death and dying was felt to be particularly difficult within the Israeli culture at this time. The 
interrogative item format (Table S3) and the section on outcomes related to each item (not shown) 
were found difficult to understand, and rate; the explanation paragraph of each item was considered 
complex; five of the 14 items were judged too taxing. As a result, the following changes were made to 
the first version: an affirmative item format was used; the list of outcomes attached to each question 
was removed; the explanation paragraph of each item was simplified; five items were removed (Table 
S3).  
 
Survey implementation, and findings  
Between July and December 2017, the online survey was carried out in all the task force countries, 
except Israel (see above). Participation was overall good, except for the UK (Table 1).  
 
[Insert Table 1 about here] 
 
The analysis was performed on 934 participants from seven countries who provided information on 
their status (MS patient or caregiver) (Table 2). MS patients (751, 80%) outnumbered caregivers (183, 
20%). Mean patient age was 46.1 years (range 19-82); 558 (74%) were women, and 428 (57%) had 
tertiary education (college or university degree). Notably, 49% of the patients were fully ambulatory, 
and 23% had been diagnosed within the last five years, with consistent figures across all the countries 
except the Netherlands where the MS patients were more disabled, indicating that MS patients were 
interested in the topic of palliative care regardless of their clinical status. Patient employment status 






























































varied, with highest unemployment in Spain and Bulgaria (14%), and lowest values in the Netherlands 
and Denmark (0-3%). Most of the caregivers were women (72%), their mean age was 47.4 years 
(range 18-77), and 64% had tertiary education. One third of the caregivers were the patient’s spouse 
or partner. The MS patients they cared for were of similar age (p=0.39) and disease duration (χ2 3.2; 
p=0.20) albeit more disabled (χ2 48.4; p<0.001) compared to the patients who completed the survey. 
The median (interquartile range) survey completion time was 8 (5-10) minutes in patients and 8 (6 - 
11) minutes in caregivers (p=0.07).  
 
[Insert Table 2 about here] 
 
Participants replying ‘I prefer not to answer’ were consistently few among MS patients and caregivers, 
highest values were found for ‘advance care planning’ (ACP: 4% of MS patients, and 5% of caregivers), 
and ‘specialist palliative care’(3% of MS patients, and 4% of caregivers). Participants agreed or 
strongly agreed on inclusion of the nine pre-specified topics, with the lowest value for ‘ACP’ (89% of 
both patients and caregivers) and the highest value for ‘multidisciplinary rehabilitation’ (99% of MS 
patients, 97% of caregivers). These figures were close to those of the 231 participants excluded from 
the analysis as they did not provide information on  their status (data not shown). 
 
There were 569 free comments, categorized into four domains: guideline pre-specified topics (182 
comments, 32%); additional topics, pertinent to the guideline (16 comments, 3%); additional topics, 
not pertinent to the guideline (211, 37%), and outcomes (160, 28%). Table 3 reports distribution of 
the comments across the four domains by country; details on domain contents are reported in the 
legend. 































































[Insert Table 3 about here] 
 
One-third of the comments on pre-specified guideline topics were on symptom management and 
rehabilitation - it was not possible from the comments to separate rehabilitation from 
multidisciplinary rehabilitation, thus topics 1 and 2 were merged, followed by palliative care and 
specialist palliative care (23%), and by emotional and practical support for caregivers (16%).  
The two guideline-pertinent additional topics were: ‘voluntary euthanasia’ (related to question 14; 
Table S3) proposed by 12 patients from Denmark, Germany, the Netherlands, and Italy, and three 
caregivers from Denmark and Germany; ‘sheltered housing/assisted living’, proposed by one German 
patient.  
Additional topics not pertinent to the guideline population, but to MS patients at large, regarded four 
main domains: ’welfare’ (104/211 comments, 49%), ‘empowerment’ (54 comments, 25%), ‘disease 
management’ (mainly related to the MS diagnosis; 31 comments, 15%), and ‘lifestyle’ (23 comments, 
11%).  
Fourteen overarching outcomes were mentioned, which included patient outcomes (from patient 
participation and quality of life, to quality of death and dying), caregiver outcomes, care-related 
outcomes, and costs (Table 3). 
Of 934 participants, 120 (13%) commented on the survey or on the guideline project. Of those, most 
participants (110, 92%) expressed appreciation of the initiative. Ten participants (8%) reported some 
criticisms: three patients considered the survey as not exhaustive, useless, or futile; one patient 
commented that topics 8 and 9 were the same; six participants criticized the patient general section 
of the survey. 































































FGM findings  
Patient FGMs lasted 96, 105, and 110 minutes, two had seven participants, and one 11 participants 
(total n=25). The median age of the patients was 54 years (range 53–75), 19 (76%) were women, and 
the median EDSS was 8.0 (range 6.0–9.5). Caregiver FGMs lasted 120 and 79 minutes, both with five 
participants (total n=10); their median age was 56 years (range 44–86), six (60%) were women; they 
were the spouse (n=5), widow (n=2) or widower (n=1) of MS patients who died in the previous year, 
mother (n=1), and daughter (n=1). After a short introduction and ice-breaking, 30-40 minutes were 
dedicated to the description of the guideline, the main phases of its production, and the reasons for 
involving patients and caregivers from the formulation of the clinical questions. All participants 
considered the guideline a valuable and necessary instrument for all professionals caring for people 
with severe MS: physicians (included family and emergency care physicians), therapists, nurses, social 
workers, and formal and informal caregivers.  
The FGM themes, components, and illustrative citations are reported in Table 4. Participants who had 
not been in touch with palliative care benefited from the explanation and discussion, as most of them 
thought the discipline pertained exclusively to end-of-life care and cancer (citations 1-3). This was 
different for participants who had experienced palliative care (citations 4,5). End-of-life issues did 
crop up as a key guideline topic (citations 6-10). Another theme was that of requirements for severely 
affected MS patients: peer socialization (citations 11, 12); and case management, expressed by both 
relatives and patients (citations 13, 14), who often felt overwhelmed and unsupported, for instance 
after discharge from hospital and rehabilitation. Outcomes encompassed symptom control (citations 
1, 3, 4), quality of life (citation 3), role preservation (of both patient and caregiver – citations 15,16), 
participation (citation 17), competency of professionals and caregivers (citations 18, 19), quality of 






























































care (citation 5), living will (citation 7), and caregiver burden (citation 10). In Germany patients’ 
emotional well-being and quality of life were considered the most important guideline outcomes, 
while unplanned hospitalizations and costs were seen as the least important. 
 
[Insert Table 4 about here] 
The main outcomes and challenges of the patient and caregiver consultation are summarized in Table 
5. Based on these findings, the task force formulated the guideline questions, and detailed each PICO 
component (Table S4). Four of the original questions (Table S3) were deemed of lesser importance, 
and subsidiary to specific guideline questions:  original question 6 ‘early palliative care’ to PICO 
question 4; original question 8 ‘goal setting’ to PICO questions 2, 4, 5;  original question 11 
‘anticipation of crises’ to PICO question 5; and original question 12 ‘best place of palliative care’ to 
PICO questions 4, 5.  




Offering the best care possible to the highest number of patients and reducing variations in service 
delivery are key issues for most healthcare systems, and the main reason for producing clinical 
practice guidelines [13]. Involvement of health service users in clinical guideline production has long 
been advocated, but insufficiently undertaken, and the best ways to engage users remain unclear [14-
16]. Here we report the experience of an international patient and caregiver involvement, which was 
time and resource intensive, and employed a mixed method. A crucial role in this process was played 
by the NMSSs of each participating country, and particularly by a task force member who is a MS 






























































patient and also a member of the MS International Federation, and of the Danish NMSS. She was key 
in bridging the issues of the MS patients to those of the health professionals and researchers. The 
online survey allowed participation of a geographically varied population, and by being anonymous 
facilitated openness and trustworthiness. However, it required proficiency with online technology, 
and the contents of the first survey were streamlined to improve clarity and acceptability. Findings 
indicated that the survey was well accepted (skipped topics were < 5%, negative comments were 
rare) and information-rich: MS patients and caregivers consistently agreed on the inclusion of the 
nine proposed topics, and provided additional proposals and comments (Table 5).  
The FGMs allowed the explanation of the process of guideline production, the identification of 
patient-important outcomes, and deliberation about taxing issues (Table 5).  The consultation process 
as a whole was time and resource intensive (figure). It was rewarding for the formulation of key 
questions that were substantiated by patients and caregivers, and also for the recognition of 
subsidiary topics within the guideline scope.        
Limitations. The online survey contents were not linguistically validated and participation differed 
markedly between countries. The FGMs could be organized only in two countries; not all the pre-
specified guideline topics could be discussed in the FGMs; the combination of previous and current 
caregivers in the same FGM was challenging (Table 5). The need for more time devoted to the task 




MS patients and caregivers validated the nine questions devised by our task force (with HP input), 
identified additional issues related to question 14 (voluntary euthanasia, assisted suicide), sheltered 






























































housing/assisted living, case management, and client-important overarching outcomes. This led to the 
formulation of 10 PICO questions for this guideline. Our pre-planned approach to engage patients and 
caregivers from the very beginning of guideline development is in line with current recommendations 
[3,16]. This was demanding but attainable, also at an international level.  Our findings add to the 
growing body of literature showing that engaging patients in guideline development is feasible, and 
impacts the process (here, the selection and formulation of the guideline questions) [14,15,17,18].  
 
Supporting Information 
Additional Supporting Information may be found in the online version of this article:  
Supplementary Appendix. Materials and methods, acknowledgements, funding, and conflict of 
interest. 
Table S1. Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist. Items 30-32 were 
not completed as they do not imply the provision of information but a judgment on the analysis.  N.R. 
= not reported; N.A. = not applicable. 
Table S2. Focus group meeting guides. 
Table S3. The nine items (‘topics’) of the online survey (left column) are listed in the survey order. The 
14 items (‘questions’) of the first version are reported in the right column, for comparison. Items 10-
14 correspond to the removed items.  
Table S4. The 10 clinical questions formulated by the task force after completion of the consultation, 
each detailed in terms of population, intervention, comparator, outcomes, and setting. Outcomes 
reported in bold are those identified by patients and caregivers. 
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Figure legend. Flowchart and time points of the study. 
 






























































Table 1. Characteristics of the 751 multiple sclerosis patients and 183 caregivers who completed the online survey, overall and by country. For 
some variables, few data are missing. MS, multiple sclerosis. 
 




Completed no. (%) 
      Overall Patients Caregivers 
Germany 80 * 10
6
 130.000 149 / 10
5 
   227     189 (83%) 136 (  72%) 118 (87%)   18 (13%) 
The UK 63 * 10
6
 100.000 164 / 10
5
     32       17 (53%)   17 (100%)   13 (76%)     4 (24%) 
Italy 59 * 10
6
 68.000 113 / 10
5
   488    443 (91%) 388 (  87%) 334 (86%)   54 (14%) 
Spain 47 * 10
6
 42.900 102 / 10
5
   178    144 (81%)   98 (  68%)   68 (70%)   30 (30%) 
The Netherlands 17 * 10
6
 14.300 88 / 10
5
     75      60 (80%)   43 (  72%)   28 (65%)   15 (35%) 
Bulgaria 7 * 10
6
 4.250 39 / 10
5
   145    124 (86%)   92 (  75%)   77 (84%)   15 (16%) 
Serbia 7 * 10
6
 – –     58      53 (91%)   53 (100%)   22 (41%)   31 (59%) 
Denmark 6 * 10
6
 12.800 227 / 10
5
   179    169 (95%) 124 (  73%) 104 (84%)   20 (16%) 
Totals – – – 1382  1199 (87%) 951 (  79%) 764 (80%) 187 (20%) 
 


















































Table 2. Characteristics of the eight countries that participated to the online survey [8, 15] and survey participation.  UK was excluded from the 


































 No (%) 
Women 81 (69%) 252 (75%) 54 (79%) 19 (78%) 55 (71%) 16 (73%) 81 (78%) 558 (74%) 
Age, mean (SD) years 42.8 (11.6) 46.2 (11.9) 44.7 (9.8) 53.1 (8.7) 43.9 (10.2) 45.8 (12.8) 50.4 (9.4) 46.1 (11.4) 
Tertiary education 62 (53%) 157 (47%) 49 (72%) 13 (46%) 44 (57%) 13 (59%) 90 (87%) 428 (57%) 
Time from diagnosis:  
< 5 years 
5-10 years 







































































Employed, full time 
Employed, part time 
Student/homemaker 
Sick leave/retired  
Age retired 
 
















3 (  5%) 
3 (  5%) 
31 (48%) 




2 (  7%) 
3 (11%) 
18 (67%) 









1 (  5%) 
8 (36%) 
1 (  5%) 
2 (  9%) 
9 (41%) 
1 (  5%) 
 
3 (  3%) 
9 (  9%) 
22 (22%) 




62 (  8%) 
229 (31%) 
118 (16%) 
67 (  9%) 
195 (26%) 
67 (  9%) 


































































 No (%) 
Women 13 (72%) 37 (69%) 25 (83%) 13 (87%) 8 (53%) 18 (58%) 18 (90%) 132 (72%) 
Age, mean (SD) years 43.7 (13.2) 47.0 (13.4) 41.6 (12.4) 58.4 (12.7) 52.5 (9.7) 44.2 (13.8) 53.8 (12.7) 47.4 (13.6) 













1 (  6%) 





5 (  9%) 
2 (  3%) 
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10 (  6%) 
Women patient 9 (53%) 29 (54%) 15 (56%) 6 (40%) 5 (42%) 18 (58%) 10 (53%) 92 (53%) 
Patient age, mean (SD) 
years 
48.5 (17.2) 47.2 (12.8) 46.6 (13.0) 55.57 (10.2) 45.4 (13.4) 44.4 (11.1) 43.9 (13.3) 47.0 (13.1) 
Time from diagnosis:  
< 5 years 
5-10 years 







































































Employed, full time 
Employed, part time 
Student/homemaker 
Sick leave/retired  
Age retired 
 














2 (  8%) 
3 (13%) 
1 (  4%) 
4 (16%) 
13 (55%) 











1 (  7%) 














































































Table 3. Comments of multiple sclerosis (MS) patients and caregivers categorized into four domains, overall and by country. Domain contents are 














1. Symptoms management  and multidisciplinary rehabilitation (topics 1 and 2): 59/182 comments (33%); palliative care (topics 4 and 5) 41 
(23%); emotional and practical support for caregivers (topic 7): 29 (16%); advance care planning (topic 3): 19 (10%); education for 
caregivers (topic 6): 18 (10%); education and training in palliative care for MS health professionals (topic 8): 9 (5%); education and training 
in MS for palliative care professionals (topic 9): 7 (4%). 
2. ‘Voluntary euthanasia’: 15/16 comments; ‘sheltered housing/assisted living’: one comment. 
3. ’Welfare’ (104/211 comments, 49%): access/coordination of care/services (43, 20%), rights (28, 13%), employment (13, 6%), economic 
support for MS patients and caregivers (13, 6%), housing and environmental adaptations (7, 3%); ‘Empowerment’ (54 comments, 25%): MS 
information for patients, relatives, caregivers, and health professionals (49, 23%), decisional autonomy (4, 2%); ‘Disease management’ (31 
comments, 15%): competent professionals (15, 7%), patient emotional support (11, 5%), relative emotional support (5, 2%); ‘Lifestyle’ (23 
comments, 11%): diet (8, 4%), sexuality (8, 4%), and leisure (7, 3%). 
4. ‘Patient participation’ (36/160 comments, 22%), ‘Functioning’ (21, 13%), ‘Symptom burden’ (17, 11%), ‘Emotional wellbeing’ (14, 9%), 
‘Advance directive/living will’ (14, 9%), ‘Service coordination’ (10, 6%), ‘Caregiver emotional wellbeing’ (10, 6%), ‘Quality of life’ (8, 5%), 
‘Quality of death/dying’ (8, 5%), ‘Satisfaction with care/services’ (8, 5%), ‘Patient-clinician relationship’ (5, 3%), ‘Caregiver burden’ (4, 2%), 
‘Complicated bereavement’ (3, 2%), ‘Costs’ (2, 1%). 
Country Pre-specified topics
1 










 Row total 
 No (%) 
Germany 51 (28%) 10 (62%) 41 (19%) 46 (29%) 148 (26%) 
Italy 56 (31%) 1 (  6%) 100 (47%) 54 (34%)    211 (37%) 
Spain 30 (16%) 0  36 (17%) 31 (19%) 97 (17%) 
Netherlands 12 (  7%) 2 (12%) 9 (  4%)           5 (  3%) 28 (  5%) 
Bulgaria 14 (  8%) 0 2 (  1%)           6 (  4%) 22 (  4%) 
Serbia 4 (  2%) 0 9 (  4%)           4 (  2%)  17 (  3%) 
Denmark 15 (  8%) 3 (20%) 14 (  7%)         14 (  9%) 46 (  8%) 
Column total 182 (100%) 16 (100%) 211 (100%)   160 (100%) 569 



















































Table 4. The focus group meeting themes, components, and illustrative citations. Citations 1, 3-5, 7 and 10 also pertain to the theme 
‘outcomes’ and to the following components: ‘symptom burden’ (cit. 1, 3, 4), ‘quality of life’ (cit. 4), ‘satisfaction with care/service’ (cit. 
5), ‘living will’ (cit. 7) and ‘caregiver burden’ (cit. 10) . MS is multiple sclerosis; EDSS is expanded disability status scale. 



















1. I think it's irrelevant whether I have MS or cancer […] What matters to me is to be kept free of 
pain and all is done to obtain this, so that you feel well then. [Woman with MS, Hamburg] 
2. The word palliative medicine does not scare me anymore, as now I know what it means. I see it 
as a way to receive protection, if it works as it should do... [Man with MS, Berg]  
3. When she accepted the PEG [Percutaneous endoscopic gastrostomy] [...], she began to breathe 
better, to have less secretions, and to talk much better. At some point she jokingly said ‘Hey guys, 
I’m going to stand up, I’m going to be healed!’ But I’ve no idea whether it was palliative or 
curative… [73 year old widower of a MS patient who recently died, at age 70, Milan] 
4. If you continue to suffer the difficulties, the pain, the immobility and everything, it’s so hard to 
carry on with your daily life. So to me, it’s key to have a somewhat dignified life. [My husband] had 
massive drooling as he could not swallow the saliva... [The palliative physician] prescribed 
Scopolamine patches, and the drooling stopped. He no longer appeared or felt soaked all the time, 
he was definitely better: At least that problem was manageable. [51 year old widow of a MS 
patient who recently died, at age 54, Milan]  
5. I just experienced [home palliative service] with my mom who died last year of a kidney cancer. 
We lived together, just the two of us. In the hospital often you're just a number [...]. Here you have 
these people alongside who can help you, even if only to talk and to deal with these issues, a 
doubt or something, it is so important… You feel like being at the center of care. [58 year old MS 
woman, EDSS 8.5, Milan] 








6. I live alone with three caregivers: one for the day, one for the night and the third for two 
weekends a month. But I wonder what will happen to me when things will be more difficult. All 
decisions and things that one has to make, that is, when you are no longer able to settle on… what 
do you do? [59 year old MS woman, EDSS 9.0, Milan] 
7. We have to have a reasonable living will, which shows where we are, yes, with my thoughts and 
everything behind it and then properly formulated. [Woman with MS, Hamburg] 
8. This is the question that I always ask myself, what will happen next, how do I know when the 
time has come? Well, I must admit I had thought to go to Switzerland to... That is, there will be a 






























































time when […] and then how do I decide, how do I understand that the time has come to end my 
life? Fear of the future, what will happen? End-of-life choices? Hastening death? It's something I 
can’t talk about with my husband, because he says that these are arguments that he does not 
want to go into. But I do keep thinking about this. [53 year old MS woman, EDSS 8.5, Milan]. 
9. She asked me repeatedly to be brought to Lugano, rather than to Zurich, to do... , we tried to 
convince her of the meaningfulness of her life, even in such disastrous conditions, and I must say 
that two psychologists helped her to accept to stay alive. [73 year old widower of a MS patient 
who recently died, at age 70, Milan]  
10. [Euthanasia] should not be hushed up, but should simply be discussed. But just with the 
difficulty that the bandwidth may become very large and it could become just too easy and 
comfortable, so that some people could feel pressed to reduce relatives’ burden or: ask as they are 
thinking: I'm just a millstone around your neck. [Woman with MS, Hamburg] 











11. During my hospitalizations and outpatient visits, I have been in contact with other patients, 
we’ve shared our stories. Over time there have been no friendships, say, with these people, but I 
am well aware that discussing these issues is indeed something that helps. Absurdly, right now 
that I have more physical difficulties, I would need more meetings and discussions, but I don’t 
know how to do that, I don’t know who to turn to, I do not know... [53 year old MS woman, EDSS 
8.5, Milan] 
12. Having conversations can be good, because I get a lot of energy from it. One should not always 
stand there... so ‘empty’... and that’s why I always like to have the opportunity to talk more. With 
other patients, you just sit together and take your time. [Woman with MS, Berg] 
13. I need someone to help me, someone just to ask to. [Woman with MS, Berg] 
14. I was blamed by my family doctor because I turned my anger on him in an occasion, [my 
husband] had been admitted to the emergency ward, and I felt a bit abandoned. And then I 
realized that it was not the family doctor who had that [case management] role. Anyway, I felt so 








15. It's really a huge loss, because as a university teacher not being able to walk is not a problem, 
not being able to use your hands is more a problem, but if you can’t even talk is a rip off, that is 
because one has so much to say and can’t say, that is, one has to reduce sentences to short ones 
and this is a real handicap. [58 year old MS woman, EDSS 8.5, Milan] 
16. But I wanted that my son was exempted from doing the bladder catheterization [to her mom]. 
[73 year old widower of a MS patient who recently died, at age 70, Milan] 
17. I got here with a transport for disabled persons. But if on a Sunday I want to go out, to say, to 

























































a dinner with friends, the transport for disabled persons is not easy to find [...] With public 
transportation it t can happen that I get there and then the platform does not work. At that point I 
give up and go back home. I feel helpless with these small and trivial things. [53 year old MS 
woman, EDSS 8.0, Milan] 
18. We teamed up. In the last period I have to say that we set up a caregiving company, we have 
been supported by a foundation that provided us great home care. I hired a paid caregiver, who I 
educated about procedures, such as the intermittent catheterization, managing the respirators, 
and basically, she worked with me and my son and we all worked together on 24 hours. [73 year 
old widower of a MS patient who recently died, at age 70, Milan] 
19. So perhaps it was hard to make the paid caregiver understand that [my husband] preferred to 
listen to the radio, rather than watch television. To her [the paid caregiver] no, one had to watch 
televisi n... I also missed the training, because I always learned everything when it happened… , 
that is, first you have to understand what the problem is. [51 year old widow of a MS patient who 
recently died, at age 54, Milan]  
 



















































Table 5. The purposes, outcomes and challenges of the international online survey and focus group meetings. MS is multiple sclerosis: 
QOL is quality of life. 
 Literature review/expert 
consultation 
International online survey Focus group meetings 
Aims - Identify topics that 
represent opportunities for 
quality improvement within 
the guideline scope.  
- Involve guideline users. 
- Involve a geographically and 
clinically varied population of 
patients and caregivers via the 
national MS Societies.  
- Anonymous, free expression of 
participants’ views and 
preferences.  
- Involve severely affected MS 
patients, and caregivers of such 
patients. 
- Involve caregivers of recently 
deceased patients. 
- Explain/discuss the process of 
guideline production. 
- Identify outcomes important to 
patient and caregivers. 
- Explore ‘difficult’ topics and taxing 
issues. 
Outcomes - Draw up of 14 clinical 
questions.  
- Over 88% of participants 
agreed/strongly agreed on 
inclusion in the guideline of each 
of the nine pre-specified topics.  
- Consistent findings between MS 
patients and caregivers. 
- Identification of 14 outcomes 
important to the patients and 
caregivers via 160 free comments. 
- Identification of 15 free 
comments on voluntary 
euthanasia. 
- Patients need to discuss about end 
of life choices, medical assisted 
suicide, and voluntary euthanasia.  
- Identification of seven outcomes, 
related to the guideline questions: 
symptom burden, participation, 
QOL, living will, role preservation 
(of the patient and caregiver), 
caregiver burden, quality of care.  


















































Challenges - None identified.  - Variable participation across the 
countries, negligible in the UK 
(excluded from analysis).  
- Selection of online-proficient and 
well-educated participants (57% 
of the patients and 64% of the 
caregivers had college or 
university degree). 
- Time and resource consuming 
(survey set up, translation into 
the target languages, piloting, 
revision, conduction, and analysis; 
Figure). 
- Performed in only two of the nine 
guideline task force countries. 
- The combination of previous and 
current caregivers in the same 
meeting was challenging.  
- Not all the pre-specified guideline 
topics could be discussed. 
- Not a pre-planned action (no 
dedicated resources). 
 





































































































MATERIALS AND METHODS  
Construction of the international online survey, its implementation, the focus group meetings 
(FGMs), the ethics statement, and analyses. 
The task force devised a set of guideline questions based on review of the literature and expert 
consultation.  
 
Construction of the international online survey 
The preliminary survey structure consisted of six parts: an introduction to the aims of the 
consultation, with explanations on guideline, and palliative care; a consent page; a section with a 
set of guideline questions, each with a structured, short explanation of the population, 
intervention, and outcomes, followed by the statement: ‘Please express whether you 
agree/disagree on including this question in the guideline’ on a four-point Likert scale (strongly 
agree/agree/disagree/strongly disagree), plus a ‘I prefer not to answer’ option; an open section for 
additional topics to be included (up to a maximum of six topics); a demographic section with a 
common set of multiple choice items on participant age, sex, education, status (patient or 
caregiver), and specific multiple choice questions for patients (time from MS diagnosis, disability 
level, employment status) and caregivers (relation with the MS sufferer, time from MS diagnosis, 
disability level, employment status of the MS sufferer); an open section for comments on the 
survey or on the guideline project. 
The survey was devised in English, translated into the target languages by appointed task force 
members with help from the National MS Societies (NMSSs), and then it was discussed at 
dedicated meetings at the Danish and Israel NMSSs, and piloted/debriefed on MS patients in 






























































Bulgaria, Germany, Italy, Serbia, the Netherlands, and the UK. The final version of the survey was 
then produced, translated, and hosted at the University of Hamburg, Eppendorf (EFS Survey® 
software, compliant with HIPAA regulations). The survey was CHERRIES-compliant [7], except for 
one checklist item as it was not possible to customize a completeness check, giving respondents 
the opportunity to review and change their responses at the end of survey completion.  
 
Survey implementation  
An invitation letter, with an email contact to receive further information, and the survey link was 
posted on the NMSS websites. NMSS invitation via the social media was also envisaged. Each 
invitation was scheduled to limit overlap with other NMSS surveys. The invitation was posted for 
2-4 weeks, and feedback on participation was provided to the NMSS on a weekly basis. The pre-
specified minimum number of participants was 50 in countries with ≥ 40 million inhabitants, and 
20 in countries with < 40 million inhabitants [8]. The survey was anonymous to promote openness 
and trustworthiness and could be accessed only once from a given IP address, to prevent multiple 
entries from the same user. Completion time was recorded. After survey closure, the open section 
text was translated into English by the appointed task force members with help from the NMSSs. 
Two researchers (AG, AF) coded the open section on additional topics independently and jointly as 
follows: they devised two lists of response categories, one for the interventions and one for the 
outcomes; additional categories identified during the coding process were included to the 
pertinent list; if a comment included multiple topics, it was coded it into multiple categories.  A 
third researcher (AS) was involved in case of difficult attribution. We excluded from the analysis 
those cases in which, in the demographic section, it was not specified whether the participant was 
a person with MS or a caregiver.  
 






























































Focus Group Meetings (FGMs)  
We addressed the guideline questions using a qualitative approach, inviting severely affected MS 
patients and caregivers who were interested in palliative care to participate in FGMs. The 
caregiver FGMs also included caregivers of MS patients who had died in the preceding 1-5 years. 
The FGMs were held in parallel to the online survey in clinical settings in Milan (Foundation C. 
Besta) and Berg (Marianne-Strauß-Klinik). In Hamburg they took place in a local patient self-help 
organization. In Milan and Hamburg participants were MS outpatients, and patients’ relatives; in 
Berg they were MS inpatients, residents of the clinic nursing home and patients’ relatives. As the 
contents of the first version of the survey were streamlined to improve clarity and acceptability, a 
further FGM objective was to consider the removed topics. Four FGMs were planned, two of 
severely affected MS patients, and two of caregivers. Each FGM had 5 to 10 participants with two 
moderators (SV and AS in Italy, SK, ACR, and BBR in Germany). In the Milan FGM of patients a 
research assistant also attended, to help participants (e.g. in drinking, changing position).  One 
moderator (facilitator) engaged participants, promoted exchange, modulated conflicts, ensuring 
the topics were adequately covered and allowing sufficient time for exploration of pertinent issues 
arising. The co-moderator helped the moderator, took notes, oversaw the audio recording and 
otherwise assisted as necessary. The facilitator first explained the purpose of the meeting, 
encouraged participants to introduce themselves, then explained the technical elements of 
guideline development (in Milan, aided by a power point presentation). After discussion of each 
guideline question the facilitator summarized major points arising, and asked whether all concerns 
had been fully aired. He then explored additional topics, and related outcomes. In Germany each 
participant rated outcome importance on a questionnaire at the end of the FGM. The consolidated 
criteria for reporting qualitative studies (COREQ) checklist is reported in Table S1; the FGM guides 
(produced by SK and revised by SV and AS) are reported in Table S2. 
































































The guideline protocol was approved by the ethics committee of the Foundation C. Besta (ref. no. 
34, 2016). The qualitative study (i.e. FGMs) was approved by the ethics committee of the 
Foundation C. Besta (ref. no. 43, 2017), and by the ethics committee of the University of Lübeck 
(ref. no. 17-307, 2017). 
 
Statistical analysis 
The analyses were performed comparing responses obtained from the patients and the caregivers. 
Those participants who did not provided information about their status (patient or caregiver) were 
excluded from the analysis. 
Categorical variables were summarized as numbers and percentages, and compared by χ2 or 
Fisher’s exact test; continuous variables were summarized as means and SD or medians with 
interquartile ranges, and compared by ANOVA or Wilcoxon rank-sum test. Normality and equality 
of variance assumptions were tested using Shapiro-Wilk’s and Bartlett’s tests, respectively.  
 
Qualitative analysis 
Each FGM transcript was analyzed by moderators using thematic analysis (deductive approach) 
[3]. As we were particularly interested in understanding patient values we thought that MS 
patients and their caregivers would have been more prone to discuss in a dedicated setting the 
guideline questions. In doing so we expected to find across the data themes mainly related to the 
clinical questions. The deductive qualitative analysis was linked to the pre-formed questions and 
themes derived from the literature and consensus, and was not aimed to produce an 
interpretative model. The two moderators analyzed the transcripts independently; then, analyses 






























































produced by each moderator were compared, and a consensus report was produced. In Italy the 
report was submitted to meeting participants for review (respondent validation). The FGM reports 
were then translated into English, and a joint report produced.  
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Table S1. Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist. Items 30-32 were not completed 
as they do not imply the provision of information but a judgment on the analysis. N.R. = not reported; N.A. = not 
applicable. 
Topic Description/Paper quotation  Section where 
reported in paper 
Domain 1: Research team and reflexivity 
Personal characteristics 
1. Interviewer/facilitator ‘Each FGM had […] two moderators (SV and AS in Italy, SK, ACR, 
and BBR in Germany). One moderator (facilitator) engaged 
participants, promoted exchange, modulated conflicts, ensuring 
the topics were adequately covered and allowing sufficient time 
for exploration of pertinent issues arising. The co-moderator 
helped the moderator, took notes, oversaw the audio recording 






2. Credentials MD (SV, BBR, AS), PhD in health sciences (SK), MSc (ACR) N.R. 
3. Occupation SV was head of Research Unit at the Palliative Care Department, 
Fondazione FARO, Turin; AS was head of the  Neuroepidemiology 
Service, Foundation IRCCS Istituto Neurologico C. Besta, Milan; 
Italy.  
SK was head of the Nursing Research Unit,  Institute of Social 
Medicine and Epidemiology, University of Lübeck, Lübeck; ACR was 
research fellow at the Institute of Neuroimmunology and Multiple 
Sclerosis, University Medical Center Hamburg-Eppendorf; BBR was 
staff neurologist and  palliative physician at the Marianne-Strauß-
Klinik, Berg; Germany.  
N.R. 
4. Gender Two moderators were men (SV, SK), and three were women (AS, 
ACR, BBR). 
N.R. 
5. Experience & training AS, SV, SK, ACR were experienced in qualitative research. BBR was 
trained by SK for the purpose of this study. 
N.R. 
Relationship with participants 
6. Relationship 
established 
Patient FGMs: AS was the treating neurologist of one patient, and   
BBR of 11 patients. 
Caregiver FGMs: SV had been the referring palliative physician of 
one patient. BBR was the treating neurologist of 5 patients whose 
caregivers participated in the FGM. 
The other moderators did not have any relationship with 
participants before the FGM. 
N.R. 
7. Participant knowledge 
of the interviewer 
See description of  item 6 above. - 
8. Interviewer 
characteristics 
SK, SV, ACR were part of the EAN Guideline Task Force. ACR and 
BBR were part of the Patient Consultation Panel of the Task Force. 
These characteristics and reasons for doing the research were 
communicated to the participants of the FGM prior to the survey. 
N.R. 
 
Domain 2: Study design 
Theoretical framework 
9. Methodological 
orientation & Theory 
‘Each FGM transcript was analyzed by moderators using thematic 
analysis (deductive approach) .’ 
Appendix 
Participant selection 
10. Sampling We used a  purposive approach to select participants: 
 ‘We addressed the guideline questions using a qualitative 
Appendix 
 






























































approach, inviting severely affected MS patients and caregivers 
who were interested in palliative care to participate in FGMs. The 
caregiver FGMs also included caregivers of MS patients who had 
died in the preceding 1-5 years. The FGMs were held in Italy 
(Foundation C. Besta, Milan) and Germany (University Medical 
Center, Hamburg; Marianne-Strauß-Klinik, Berg) in parallel to the 
online survey. In Milan and Hamburg participants were MS 
outpatients, and patients’ relatives; in Berg they were MS 










Eligible participants were first identified by the centre physician, 
who informed them of study aims and procedures face-to-face or 
by telephone, and asked them to provide informed consent to 
participate in the FGM. Consenting participants were then 
contacted by the FGM moderator or by a research assistant, who 
further detailed the FGM procedure, and checked participant’s 
availability on the scheduled date/time. Before the FGM, each 




12. Sample size ‘Four FGMs were planned, two of severely affected MS patients, 
and two of caregivers. Each FGM had 5 to 10 participants with two 
moderators.’  
Appendix 
13. Non-participation Of 29 patients contacted  4 refused to participate for the following 
reasons: difficulty in coming to the center (n=2), uneasy about 
sharing their personal views (n=2).  
Of 16 caregivers contacted 6 refused to participate for the 
following reasons: unavailable on the scheduled date  (n=2),  
uneasy about sharing their personal views (n=2), caregiving duties 








14. Setting of data 
collection 
‘The FGMs were held in parallel to the online survey in clinical 
settings in Milan (Foundation C. Besta) and Berg (Marianne-Strauß-
Klinik). In Hamburg they took place in a local patient self-help 
organization. In Milan and Hamburg participants were MS 
outpatients, and patients’ relatives; in Berg they were MS inpatients, 




15. Presence of non-
participants 
In the Milan FGM of patients one research assistant was present in 
the meeting room at disposal of the disabled patients who needed 
help (e.g. in drinking, changing position). No additional participants 
were present in the German FGMs. 
N.R. 
16. Description of 
sample 
‘Patient FGMs […] The median age of the patients was 54 years 
(range 53–75), 19 (76%) were women, and the median EDSS was 8.0 
(range 6.0–9.5).  
Caregiver FGMs […] ‘their median age was 56 years (range 44–86), 
six (60%) were women; they were the spouse (n=5), widow (n=2) or 
widower (n=1) of MS patients who died in the previous year, mother 
(n=1), and daughter (n=1)’.  
Results 
Data collection 
17. Interview guide ‘[…] the FGM guides (produced by SK and revised by SV and AS) are 




18. Repeat interviews No FGM was repeated. N.R. 
19. Audio/visual 
recording 
‘The co-moderator helped the moderator, took notes, oversaw the 
audio recording and otherwise assisted as necessary.’  
Appendix 
 
20. Field notes ‘The co-moderator helped the moderator, took notes, oversaw the Appendix 































































audio recording and otherwise assisted as necessary.’   
21. Duration ‘Patient FGMs lasted 96, 105, and 110 minutes, […]’.  
‘Caregiver FGMs lasted 120 and 79 minutes, […]’.  
Results 
 
22. Data saturation We did not consider the achievement of data saturation. FGMs were 
added to the online survey (protocol amendment) to address the 
importance of the guideline PICOs qualitatively, and to explore 
sensible themes that were not included in the survey. The number 
of FGMs was pre-set to 4, based on the available resources and the 
project timeline. 
N.R. 
23. Transcripts returned ‘A report of this analysis was submitted to meeting participants for 





Domain 3: Analysis and findings 
Data analysis 
24. Number of data 
coders 
SV and AS  analyzed the Italian FGMs.  SK, ACR and BBR analyzed the 
German FGMs.   
N.R. 
25. Description of the 
coding tree 
Each FGM transcript was analyzed by moderators using thematic 
analysis (deductive approach) [3]. The two moderators analyzed the 
transcripts independently; then, analyses produced by each 
moderator were compared, and a consensus report was produced. 
In Italy the report was submitted to meeting participants for review 
(respondent validation). The FGM reports were then translated into 
English, and a joint report produced.  
Appendix 
 
26. Derivation of themes See description of  item 25 above (deductive approach). 
The deductive analysis was linked to the pre-formed questions and 
themes derived from the literature and consensus, and was not 
aimed to produce an interpretative model. 
- 
Discussion 
27. Software Not used. N.R. 
28. Participant checking  ‘After discussion of each guideline question the facilitator 
summarized major points arising, and asked whether all concerns 
had been fully aired. […]  In Italy the report of this analysis was 









Illustrative quotations were presented in the manuscript. 
Quotations are identified by a short description of the participant 
(patient or caregiver, age, city).  
Table 4 
30. Data & findings 
consistent 
–   
31. Clarity of major 
themes 
–  
32. Clarity of minor 
themes 
–  
































































Table S2. Focus group meeting guides. MS is multiple sclerosis. 
 
Focus group meeting guide - MS patients 
 
1. Introduction, organisational issues 
Introduction of facilitators and 
participants 
Introduction and information 
on the group interview  
Background, MS experience, 
duration, audio-recording, data 
protection, ethics, etc. 
Short introduction to the topic  Why are we here? 
 
“We want to develop a guideline 
for the care of people with severe 
MS. The guideline should help 
patients, carers, and physicians to 
make good decisions on care […]” 
Longer introduction to the 
topic & the method 
 
 
 What are clinical practice 
guidelines? 
 
 What is the role of clinical 
practice guidelines? 
 
 What has been done 
already? (i.e. online survey 
& discussions among 
experts) 
 What is a focus group and 
why do we consider it 
relevant here? 
 How do we define “severe 
MS”? What is palliative 
care? Is it all about dying? 
 At the end: Example 
question from the online  
survey; what could a 
recommendation look like 
 Graphical presentation 

















 Example recommendation 
(from the online survey): 
Topic 6: Education and 
training programs for family 
members and caregivers of 
patients with severe MS.  
Education and training 
programs (e.g. classes, 
booklets, CDs) directed to help 
the caregiving role of family 
members and caregivers of 
patients with severe MS 
 It could look like: Training 
programmes are beneficial for 
caregivers of people with 
severe MS (strong 
recommendation) 
 It could also look like: 
Training programmes could be 
































































considered for caregivers of 
people with severe MS (weak 
recommendation) 
 short Power Point 
presentation / or flipchart 
2. Interventions  




Name, reason to take part 
Questions on interventions 
(list of topics) 
 
 Introduction of topics 1-3 
from the survey  
(5 min. discussion about 





 Introduction of topics 4-6 
from the survey 
(5 min. discussion about 





 Introduction of topics 7-9 





 5 min. discussion about 
inclusion in the guideline 
 Missing topics 
Introduce topics 1-3: “Please 
take a look at these 
interventions for people with 
severe MS. Should each of 
these be included in the 
guideline?” “Do you see any 
problems/barriers/challenges?” 
 
Introduce topics 4-6: “Now 
please look at these three 
topics. Should all of them be 
included in the guideline?”  




Introduce topics 7-9: “And 
finally, 3 more interventions for 
people with severe MS. Should 
each of these be included in the 




Are there any additional topics 
that you would include in this 
guideline? 
3. Outcomes  - caregivers  
Discussion of outcomes of 
interventions for caregivers 
 Which outcomes are important 
for caregivers of people with 
severe MS? 
Introducing list of outcomes: 
“For caregivers of people with 
severe MS, what would be 
relevant outcomes to show 
how successful any of these 
interventions are?”  
“Are there any additional 
outcomes caregivers of people 
with severe MS might consider 
important in this context?” 
































































Record additional outcomes on 
flipchart. 
4. Outcomes - people with MS  
Short discussion on 
adjustments of outcomes for 





 Which outcomes are 
important for people with 
severe MS? 
“Do you think people with 
severe MS would consider 
different outcomes to be 
relevant indicators of success 
for any of these interventions?” 
In case new outcomes are 
mentioned: Record on flipchart 
(in different colour) 
5. End-of-life care  
Interventions & outcomes 
caregiver 
Interventions & outcomes 
people with MS 
 Final round especially 
addressing end of life care 
and dying. 
“We have talked a lot about 
interventions that could 
support people with MS and 
their carers and what results 
you would prefer from these 
interventions. We´d now like to 
take a final focus on topics that 
cover issues of dying and 
bereavement and are hence 
particularly sensitive.” 
Introduce each of the following 
questions, step by step:  
1) For patients with 
severe MS and their 
caregivers what are the 
benefits of a proactive, 
anticipation of crises 
approach? 
2) For patients with 
severe MS and their 
caregivers which is the 
best place of 
(palliative) care? 
3) For patients with 
severe MS, what are 
the benefits of 
discussing with health 
professionals their wish 
of hastening death? 
After each question: “Should 
this question be included in the 
guideline?” “Do you see any 
problems/barriers/challenges?” 
 
































































“Are there any additional 
particularly sensitive 
aspects/questions to be 
included in this guideline?” 
(record on flip chart)   
Feedback Question for further feedback, 
concerns  
“Any open issues?” 
Questionnaire (in Germany 
only) 
Ask participants to fill in 
questionnaire on baseline data 
and rating of relevance of 
outcomes 
“As a final request, we would 
like to ask you to fill in this 
anonymous questionnaire 
asking for a few details about 
yourself and for your personal 
rating of each outcome 
regarding its relevance.” 
Send-off  Information that the facilitators 
can be contacted in the future 






































































Focus group meeting guide - Caregivers of MS patients 

1. Introduction, organisational issues 
Introduction of facilitators and 
participants 
Introduction and information 
on the group interview  
Background, MS experience, 
duration, audio-recording, data 
protection, ethics, etc. 
Short introduction to the topic  Why are we here? 
 
“We want to develop a guideline 
for the care of people with severe 
MS. The guideline should help 
patients, carers, and physicians to 
make good decisions on care.” 
Longer introduction to the 
topic & the method 
 
 
 What are clinical practice 
guidelines?     
 What has been done 
already? (Online survey & 
discussions among 
experts) 
 What is a focus group and 
why do we consider it 
relevant here? 
 How do we define “severe 
MS”? What is palliative 
care? Is it all about dying? 
 At the end: Example 
question from survey, 
what could a 
recommendation look like  
 Graphical presentation 













 Example recommendation 
(from online survey): Topic 6: 
Education and training 
programs for family members 
and caregivers of patients 
with severe MS.  
Education and training 
programs (e.g. classes, 
booklets, CDs) directed to help 
the caregiving role of family 
members and caregivers of 
patients with severe MS 
 It could look like: Training 
programmes are beneficial for 
caregivers of people with 
severe MS (strong 
recommendation) 
 It could also look like: 
Training programmes could be 
considered for caregivers of 
people with severe MS (weak 
recommendation) 
 Short Power Point 
presentation /or flipchart 
 
 
































































2. Interventions  
Introduction participants & 
first round 
Introduction round  Name, reason to take part, 
how long affected by MS, 
informal caregiver 
Questions on interventions 
(list of topics) 
 
 Introduction of topics 1-3 
from the survey  
(5 min. discussion about 




 Introduction of topics 4-6 
from the survey 
(5 min. discussion about 





 Introduction of topics 7-9 
from the survey 
 5 min. discussion about 




 Missing topics 
Introduce topics 1-3: “Please 
take a look at these 
interventions for people with 
severe MS. Should each of 
these be included in the 
guideline?” “Do you see any 
problems/barriers/challenges?” 
 
Introduce topics 4-6 : “Now 
please look at these three 
topics. Should all of them be 
included in the guideline?”  




Introduce topics 7-9: “And 
finally, 3 more interventions for 
people with severe MS. Should 
each of these be included in the 
guideline?” Do you see any 
problems/barriers/challenges?” 
Are there any additional topics 
that you would include in this 
guideline? 
3. Outcomes – people with MS  
Discussion of outcomes of 
interventions for people with 
MS  
 
 Which outcomes are important 
for people with severe MS? 
Introducing list of outcomes: 
“For people with severe MS, 
what would be relevant 
outcomes to show how 
successful any of these 
interventions are?”  
“Are there any additional 
outcomes people with severe 
MS might consider important in 
this context?” Record 
additional outcomes on 
flipchart. 
4. Outcomes caregivers 
Short discussion on 
adjustments of outcomes for 
caregivers of people with 
 Which outcomes are 
important for caregivers of 
“Do you think caregivers of 
people with severe MS would 
consider different outcomes to 
































































severe MS people with severe MS? be relevant indicators of 
success for any of these 
interventions?” In case new 
outcomes are mentioned: 
Record on flipchart (in different 
colour) 
5. End-of-life care   
Interventions & outcomes –
people with MS 
Interventions & outcomes - 
caregiver 
 
 Final round especially 
addressing end of life care 
and dying.  
“We have talked a lot about 
interventions that could 
support people with MS and 
their carers and what results 
you would prefer from these 
interventions. We´d now like to 
take a final focus on topics that 
cover issues of dying and 
bereavement and are hence 
particularly sensitive.” 
Introduce each of the following 
questions, step by step:  
4) For patients with 
severe MS and their 
caregivers what are the 
benefits of a proactive, 
anticipation of crises 
approach? 
5) For patients with 
severe MS and their 
caregivers which is the 
best place of 
(palliative) care? 
6) For patients with 
severe MS, what are 
the benefits of 
discussing with health 
professionals their wish 
of hastening death? 
After each question: “Should 
this question be included in the 
guideline?” “Do you see any 
problems/barriers/challenges?” 
 
“Are there any additional 
particularly sensitive 
aspects/questions to be 
included in this guideline?” 
(record on flip chart)   

































































Feedback Question for further feedback, 
concerns  
“Any open issues?” 
Questionnaire (in Germany 
only) 
Ask participants to fill in 
questionnaire on baseline data 
and rating of relevance of 
outcomes 
“As a final request, we would 
like to ask you to fill in this 
anonymous questionnaire 
asking for a few details about 
yourself and for your personal 
rating of each outcome 
regarding its relevance.” 
Send-off  Information that the facilitators 
can be contacted in the future 



































































Table S3. The nine items (‘topics’) of the online survey (left column) are listed in the survey order. The 14 
items (‘questions’) of the first version are reported in the right column, for comparison. Items 10-14 
correspond to the removed items. MS is multiple sclerosis. 
Item 
no. 
Second (final) version First version 
1 Topic 1: Symptomatic treatments for 
patients with severe MS. 
 
A symptomatic treatment is any treatment 
(medicinal product, complementary and 
alternative medicine) that eases the MS 
symptoms (for example pain, fatigue, 
spasticity) without addressing the basic 
cause of the disease. 
Question 13: For patients with severe MS 
what are the benefits of symptomatic 
treatments? 
 
Who: Patients with progressive MS and 
complex needs. 
What: Any treatment (medicinal products, 
complementary and alternative medicines) 
that eases the MS symptoms (e.g. pain, 
fatigue, spasticity) without addressing the 
basic cause of the disease. 
2 Topic 2: Multidisciplinary rehabilitation for 
patients with severe MS. 
 
Multidisciplinary rehabilitation is a 
coordinated intervention, in two or more 
disciplines (for example physiotherapy, 
orthotics, psychology, urology, sexology). 
The goal of multidisciplinary rehabilitation 
is to reduce patient symptoms, improve 
functional independence and social 
participation. 
Question 2: For patients with severe MS 
what are the benefits of multidisciplinary 
rehabilitation? 
 
Who: Patients with progressive MS and 
complex needs. 
What: Coordinated intervention, delivered 
by two or more disciplines (e.g. nursing, 
physiotherapy, occupational therapy, 
speech therapy, orthotics, dietetics, social 
work, psychology, neuropsychology, 
urology, sexology) in conjunction with 
physician consultation (neurologist or 
rehabilitation medicine physician), which 
aims to limit patient symptoms, and 
enhance functional independence and 
maximize participation. 
3 Topic 3: Timely engagement in advance 
care planning for patients with severe MS. 
 
In advance care planning the patient and 
his/her physician establish future goals of 
care in the end-of-life phase, based on 
shared discussion and on the patient values 
and preferences. Advance care planning 
can lead to an advance directive, which is a 
written statement about a person’s 
preferences regarding future medical 
decisions. 
Question 3: For patients with progressive 
MS what are the benefits of early 
engagement in advance directives / 
advance care planning? 
 
Who: Patients with progressive MS. 
What: Advance directives, advance care 
planning, and end of life choices are 
individually tailored processes of discussion 
between a patient and his or her healthcare 
provider regarding concerns, goals, 
preferences, prognosis and future care, 






























































activated when the patient is in a relatively 
stable disease phase. 
4 Topic 4: Palliative care for patients with 
severe MS. 
 
Palliative care is a way of caring that 
includes the consideration of all aspects of 
a person – his/her physical, emotional, 
social and spiritual needs. This is a 
comprehensive approach to care for 
anyone who has a serious illness and has 
increasing needs. Palliative care is 
applicable early in the course of illness, in 
conjunction with other therapies that are 
intended to prolong life. 
Question 1: For patients with severe MS 
what are the benefits of palliative care? 
 
Who: Patients with progressive MS and 
complex needs. 
What: Palliative care is a comprehensive 
approach to care for anyone who has a 
serious illness and has increasing needs. It 
represents a way of caring that includes the 
consideration of all aspects of a person – 
his/her physical, emotional, social and 
spiritual needs. 
5 Topic 5: Specialist palliative care (hospice 
care) for patients with severe MS in 
unstable, deteriorating or dying phase of 
the disease. 
 
Specialist palliative care (hospice care) is a 
specific model of (palliative) care for 
patients affected by progressive relentless 
diseases. It is usually provided in hospice or 
at home, but can be offered in other 
settings (e.g. in hospital or care homes). It 
is aimed at reducing suffering, improving 
quality of life and enable planning for the 
end of life. It can also provide support and 
education to carers, reducing long term 
issues in bereavement. 
Question 7: For patients with severe MS 
what are the benefits of specialist palliative 
care (hospice care) in unstable, 
deteriorating or dying phase of the disease? 
 
Who: Patients with progressive MS in 
unstable, deteriorating or dying phase. 
What: Specialist palliative care (hospice 
care) is a specific model of multidisciplinary 
care aimed at providing help in different 
settings (mainly at home or in hospice, but 
can be offered in hospital or care homes) to 
patients affected by progressive relentless 
diseases. It is aimed at reducing suffering, 
improving residual quality of life and 
planning the end of life. It can also provide 




Topic 6: Education and training programs 
for family members and caregivers of 
patients with severe MS. 
 
Education and training programs (e.g. 
classes, booklets, compact disks) directed 
to help the caregiving role of family 
members and caregivers of patients with 
severe MS. 
Question 4: For caregivers of patients with 
severe MS what are the benefits of 
education and training interventions? 
 
Who: Caregivers (informal, such as family 
and friends or formal, such as paid helpers) 
of patients with progressive MS and 
complex needs. 
What: Education and training programs 
(e.g. classes, booklets, CDs) to help the 
caregiving role. 
7 Topic 7: Practical and emotional support to Question 5: For caregivers of patients with 






























































 family members and caregivers of patients 
with severe MS. 
 
The provision of practical support (e.g. 
advice, help with daily living 
needs/housework, respite care) and 
emotional support (e.g. counseling, support 
groups) to family members and caregivers 
of patients with severe MS. 
severe MS does the provision of support 
provide benefits for them? 
 
Who: Caregivers (informal, such as family 
and friends or formal, such as paid helpers) 
of patients with progressive MS and 
complex needs, including caregivers of 
recently deceased MS patients. 
What: Practical and emotional support, 
included bereavement support. 
8 
 
Topic 8: Education and training in palliative 
care for MS health providers, such as 
neurologists, physiatrists, nurses, 
psychologists. 
Question 9: For MS health professionals 
what are the benefits of training and 
education in palliative care? 
 
Who: MS health professionals (e.g. 
neurologists, physiatrists, nurses, 
psychologists, therapists). 




Topic 9: Education and training in MS care 
for palliative care health providers, such as 
palliative care physicians, nurses, 
psychologists. 
Question 10: For palliative care health 
professionals what are the benefits of 
training and education in MS care? 
 
Who: Palliative care health professionals 
(e.g. palliative care physicians, nurses, 
psychologists). 




 Question 6: For patients with severe MS 
should palliative care be considered early in 
the disease trajectory? 
 
Who: Patients with progressive MS and 
complex needs. 
What: Palliative care is a way of caring that 
includes the consideration of all aspects of 
a person – his/her physical, emotional, 
social and spiritual needs. This is a 
comprehensive approach to care for 




 Question 8: For patients with severe MS 
and their caregivers does the setting of 
goals of treatment lead to benefit? 
 






























































Who: Patients and caregivers (informal, 
such as family and friends or formal, such as 
paid helpers) of patients with progressive 
MS and complex needs. 
What: Goal setting, sometimes referred to 
as goal planning, is the formal process 
whereby a health professional or team 
together with the patient and/or his family 
negotiate goals that are patient-specific, 
relevant, achievable and realistic. 
12 
 
 Question 11: For patients with severe MS 
and their caregivers what are the benefits 
of a proactive, anticipation of crises 
approach? 
 
Who: Patients with progressive MS and 
complex needs, and their caregivers 
(informal, such as family and friends or 
formal, such as paid helpers). 
What: A proactive, anticipation of crises 
care approach, like the “Just in case kit” – a 
box containing easy to use and clearly 
explained prescriptions and drugs for 
controlling shortness of breath episodes. 
This approach can be used for other 
symptoms or episodes occurring at patient 
home, helping to avoid hospitalization. 
13 
 
 Question 12: For patients with severe MS 
and their caregivers which is the best place 
of (palliative) care? 
 
Who: Patients with progressive MS and 
complex needs, and their caregivers 
(informal, such as family and friends or 
formal, such as paid helpers). 
What: Palliative care delivered at home, on 
an outpatient basis, respite care, special 




 Question 14. For patients with severe MS, 
what are the benefits of discussing with 
health professionals their wish of hastening 
death? 
 
Who: Patients with progressive MS and 
complex needs. 
What: Open discussion of the wish to 































































hasten death, a reaction to a suffering 
which can occur in patients with life-
threatening conditions. 






























































Table S4. The 10 clinical questions formulated by the task force after completion of the 
consultation, each detailed in terms of population, intervention, comparator, 
outcomes, and setting. Outcomes reported in bold are those identified by patients and 
caregivers. 
ADL is activity of daily living; CCT is controlled clinical trial; EDSS is expanded disability 
status scale; MS is multiple sclerosis; QOL is quality of life; RCT is randomized 
controlled trial.  
1. For patients with severe MS what are the effects of symptomatic treatments on patient 
outcomes, caregiver outcomes, and costs?  
Population  
Patients with primary or secondary progressive MS and complex needs, 
EDSS > 6.0,  and specific disabling symptoms (as e.g. fatigue, pain, 
incontinence, spasticity) 
Intervention 
Any symptomatic treatment targeting one or more of the specified 
disabling symptoms 
Comparator Usual/standard care, placebo, other symptomatic treatment option 
Outcomes (max 7) 
1. Symptom burden 
2. ADL/participation 
3. QOL 
4. Unplanned hospitalizations/hospital deaths 
5. Costs 
6. Caregiver burden 
7. Caregiver QOL 
Setting Any (e.g. home, hospital, care home, hospice) 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 






































































2. For patients with severe MS what are the effects of multidisciplinary rehabilitation on 
patient outcomes, caregiver outcomes, and costs?  
Population  
Patients with primary or secondary progressive MS and complex needs, 
EDSS > 6.0 
Intervention 
”A coordinated intervention, delivered by two or more disciplines in 
conjunction with physician consultation (neurologist or rehabilitation 
medicine physician), which aims to limit patient symptoms, and 
enhance functional independence and maximise participation. The 
multiple disciplines include nursing, physiotherapy, occupational 
therapy, speech therapy, orthotics, dietetics, social work, 
psychology or neuropsychology” [Khan F, et al. Multidisciplinary rehabilitation 
for adults with multiple sclerosis. Cochrane Database of Systematic Reviews 2007, Issue 
2. Art. No.: CD006036] 
Comparator 
Usual/standard care, other form of rehabilitation,  other 
pharmacological  or non-pharmacological intervention (e.g. education, 
training)   
Outcomes (max 7) 





6. Caregiver burden 
7. Caregiver QOL 
Setting In-patient, out-patient, home-based, community-based 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 






































































3. For patients with severe MS what are the effects of advance care planning on patient 
outcomes, caregiver outcomes, and costs?  
Population  
Patients with primary or secondary progressive MS and complex needs, 
EDSS > 6.0, or patient-caregiver dyads 
Intervention 
Advance care planning (ACP) is any process that enables individuals to 
identify their values, reflect upon the meanings and consequences of 
serious illness scenarios, define goals and preferences for future 
medical treatment and care, and discuss these with family and health-
care providers. ACP addresses individuals’ concerns across the physical, 
psychological, social, and spiritual domains. It encourages individuals to 
identify a personal representative and to record and regularly review 
any preferences, so that their preferences can be taken into account 
should they, at some point, be unable to make their own decisions [e.g. 
Rietjens JAC, et al. Definition and recommendations for ACP: an international consensus 
supported by the EAPC. Lancet Oncol 2017; 18: e543–51] 
Comparator Usual/standard care 
Outcomes (max 7) 
1. Patient QOL 
2. Unwanted hospitalizations/treatments, hospital deaths 
3. Completion of advance directive/living will 
4. Consistency of care with patient goals and preferences (respect of 
end of life choices)    
5. Caregiver burden 
6. Caregiver QOL and mood 
7. Costs 
Setting Any (in-patient, out-patient, home, care home, hospice) 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































4. For patients with severe MS what are the effects of general palliative care on patient 
outcomes, caregiver outcomes, and costs?   
Population  
Patients with primary or secondary progressive MS and complex needs, 
EDSS > 6.0, or patient-caregiver dyads 
Intervention 
General palliative care is provided by primary care professionals and specialists 
treating patients with life-threatening diseases who have good basic palliative 
care skills and knowledge. Professionals who are involved more frequently in 
palliative care, such as oncologists or geriatric specialists, but do not provide 
palliative care as the main focus of their work, still may have acquired special 
education and training in palliative care and may provide additional expertise. 
[Radbruch L, Payne S and the Board of Directors of the EAPC. White Paper on 
standards and norms for hospice and palliative care in Europe: part 1. 
European Journal of Palliative Care 2009; 16(6):278-289] 
Comparator Usual/standard care 
Outcomes (max 7) 
1. Symptom burden 
2. QOL 
3. Unplanned hospitalizations/treatments, hospital deaths 
4. Quality of death/dying 
5. Costs 
6. Caregiver burden/mood symptoms/QOL 
7. Complicated bereavement 
Setting Any (e.g. home, hospital, care home, hospice) 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































5. For patients with severe MS what are the effects of specialist palliative care on patient 
outcomes, caregiver outcomes, and costs?   
  
Population  
Patients with primary or secondary progressive MS and complex needs, 
EDSS > 6.0, or patient-caregiver dyads 
Intervention 
Specialist palliative care describes services whose main activity is the 
provision of palliative care […] Specialist palliative care services require 
a team approach, combining a multiprofessional team with an 
interdisciplinary mode of work. Team members must be highly qualified 
and should have their main focus of work in palliative care. [Radbruch L, 
Payne S and the Board of Directors of the EAPC. White Paper on 
standards and norms for hospice and palliative care in Europe: part 1. 
European Journal of Palliative Care 2009; 16(6):278-289] 
Comparator Usual/standard care, non-specialist palliative care 
Outcomes (max 7) 
1.Symptom burden 
2.QOL 
3.Unplanned hospitalizations/treatments, hospital deaths 
4.Quality of death/dying  
5.Costs 
6.Caregiver burden/mood symptoms/QOL 
7.Complicated bereavement 
Setting Any (e.g. home, hospital, care home, hospice) 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































6. For caregivers of patients with severe MS what are the effects of education and training 
programs on patient outcomes, caregiver outcomes, and costs? 
Population  
Primary caregivers (informal or formal) of patients with primary or 
secondary progressive MS and complex needs, EDSS > 6.0   
Intervention 
Structured education and training program on caregiving in general and 
specifically for a person with MS (classes, web-based, booklet, etc.) 
 
Comparator 
No education/training, low intensity program (e.g. information leaflet), 
usual care 
 
Outcomes (max 7) 
1. Caregiver burden 
2. Caregiver QOL 
3. Bereavement issues / complicated bereavement 
4. MS patient symptom burden 
5. MS patient ADL/participation/QOL 
6. Costs 
7. Unplanned hospitalizations 
Setting Any (home, hospital, care home, hospice) 
 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































7. For caregivers of patients with severe MS what are the effects of  practical and emotional 
support interventions on patient outcomes, caregiver outcomes, and costs? 
Population  
Primary caregivers (informal or formal) of patients with primary or 
secondary progressive MS and complex needs, EDSS > 6.0, including 
caregivers of patients deceased over the previous 6 months 
Intervention 
Structured, practical (e.g. advice, help with daily living 
needs/housework, respite care) and/or emotional support (e.g. 
counselling, support groups, involvement with specialist MS nurse or 
professional or volunteer), included bereavement support 
 
Comparator No support, low intensity intervention (e.g. information leaflet) 
 
Outcomes (max 7) 
1. Caregiver burden 
2. Caregiver QOL 
3. Bereavement issues/complicated bereavement 
4. MS patient symptom burden 
5. MS patient ADL/participation/QOL 
6. Service/care satisfaction 
7. Costs 
Setting Any (home, hospital, care home, hospice) 
 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































8. For MS health professionals what are the effects of  education and training in palliative 
care on professional outcomes, patient outcomes, caregiver outcomes, and costs? 
Population  
Health professionals (e.g. physicians, nurses, psychologists, therapists) 
directly caring for MS patients 
Intervention 
Structured education and training program in palliative care (classes, 
web-based, booklet, etc.) 
 
Comparator No education/training, low intensity program (e.g. information leaflet) 
 
Outcomes (max 7) 
1. Professional skills in palliative care 
2. Professional skills in shared decision-making/informed choices 
3. Professional wellbeing including burnout reduction/prevention 
4. MS patient QOL 
5. MS patient symptom burden 





1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































9. For specialist palliative care health professionals what are the effects of  education and 
training in MS on professional outcomes, patient outcomes, caregiver outcomes, and costs? 
Population  
Specialist palliative care (hospice) health professionals (e.g. physicians, 
nurses, psychologists, therapists, social workers)   
Intervention 
Structured education and training program in MS (classes, web-based, 
booklet, etc.) 
 
Comparator No education/training, low intensity program (e.g. information leaflet) 
 
Outcomes (max 7) 
1. Professional’s skills in MS care 
2. Professional’s skills in MS communication and shared decision 
making 
3. Professional wellbeing including burnout reduction/prevention 
4. MS patient QOL 
5. MS patient symptom burden 






1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception  or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 







Qualitative studies  
 
  






























































10. For patients with severe MS what are the effects of discussing with health professionals 
their wish to hasten death on patient outcomes and caregiver outcomes? 
Population  
Patients with primary or secondary progressive MS and complex needs, 
EDSS > 6.0, or patient-caregiver dyads 
Intervention 
Open, structured or unstructured discussion of one or more of the 
following: the patient wish to hasten death; the explicit expression of a 
wish to die; a request for euthanasia or physician-assisted suicide. 
 
Comparator Usual/standard care 
 
Outcomes (max 7) 
1. Patient QOL 
2. Patient emotional wellbeing 
3. Patient-health professional relationship 
4. Satisfaction with care/services 
5. Completion of advance care planning 
6. Caregiver emotional wellbeing 
 
Setting Any (in-patient, out-patient, home, care home, hospice) 
 
Exclusion 
1. Pediatric MS population 
2. Mixed patient population with MS patients < 50%, or MS data not 
available 
3. Severe MS patients (see ‘population’ above) < 50%, or data not 
available 
4. Published before database inception  or after December 2017 
5. Language other than English, Spanish, Danish, German, Dutch, 
Italian, Bulgarian, Serbian, Hebrew 
 
Study type 
1. Systematic reviews 
2. RCTs  
3. CCTs  
4. Observational studies 
5. Qualitative studies  
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